1Palanca-Wessels MC,Press OW.Improving the efficacy of radioimmunotherapy for non-Hodgkin lymphomas.Cancer,2010,116(4 Suppl):1126-1133.
2Goldsmith SJ.Radioimmunotherapy of lymphoma:Bexxar and Zevalin.Semin Nucl Med,2010,40(2):122-135.
3Jacobs SA,Swerdlow SH,Kant J,et al.Phase Ⅱ trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma.Clin CancerRes,2008,14(21):7088-7094.
4Schilder R,Molina A,Bartlett N,et al.Follow-up results of a phase Ⅱ study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade,follicular,or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia.Cancer Biother Radiopharm,2004,19(4):478-481.
5Nademance A,Forman S,Molina A,et al.A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell trans-plantation in patients with poor-risk or relapsed non-Hodgkin lymphoma.Blood,2005,106(8):2896-2902.
6Gibson AD.Updated results of a phase Ⅲ trial comparing ibritumomab tiuxetan with rituximab in previously treated patients with non-Hodgkin's lymphoma.Clin Lymphoma,2002,3(2):87-89.
7Capizzi RL.Targeted radio-immanotherapy with Bexxar produces durable remissions in patients with late stage low grade non-Hedgkin's lymphomas.Trans Am Clin Climatol Assoc,2004,115:255-272.
8Horning SJ,Younes A,Jain V,et al.Efficacy and safety of tositumomab and iodine-131 tositumomab(Bexxar)in B-cell lymphoma,progressive after rituximab.J Clin Oncol,2005,23(4):712-719.
9Mattes MJ,Sharkey RM,Karacay H,et al.Therapy of advanced B-lymphoma xenografts with a corbination of 90Y-anti-CD22 IgG(Epratuzumab)and unlabeled anti-CD20 IgG(Veltuzumab).Clin Cancer Res,2008,14(19):6154-6160.
10Ferrer L,Kraeber-Bodéré F,Bodet-Milin C,et al.Three methods assessing red narrow dosimetry in lymphoma patients treated with radioimmunotherapy.Cancer,2010,116(4 Suppl):1093-1100.
